{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The treatment-free interval after treatment with the combination of thalidomide, bortezomib and melphalan","dispersionType":"Standard Deviation","groups":[{"description":"Assessment of PFS made using the entire cohort","id":"OG000","title":"Phase 1/Phase 2"}],"paramType":"MEDIAN","populationDescription":"Data no longer available, only manuscript information where PFS reported for single Arm/Group of all participants","reportingStatus":"POSTED","timeFrame":"PFS was defined as the time from ASCT to disease progression or death from any cause, an average of 9 months","title":"Treatment Free Interval/PFS","type":"SECONDARY","unitOfMeasure":"months"}